Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection
In contrast, apitegromab and trevogrumab target pro-MSTN and the latent complex, which helps minimize such side effects.[75,76] An additional noteworthy finding from studies on these two antibodies is that they not only increased muscle mass but also reduced fat mass.[75,76] This supports the notion that comprehensive MSTN inhibition, from its inactive forms to the mature form, represents a promising strategy for treating muscle loss in conjunction with metabolic disorders (Fig
Encourages Sustainable Fat Loss: Supports gradual, maintainable body-composition changes rather than rapid, rebound-prone weight loss
Lancet 2021;397:97184.ArticlePubMed 48
[61, 62, 63, 64, 65] Based on World Health Organization (WHO), worldwide adult obesity has more than doubled since 1990, while adolescent obesity has quadrupled
E-values were calculated for pre-specified outcomes to assess the potential influence of unmeasured confounders 52
